People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Avicenna Biosciences, Inc. | — | Biotechnology | Series A | $17.5M | $31.5M | 2020 |
| Pique Therapeutics, Inc. | — | Biotechnology | Pre-Seed | $1.4M | $47.2M | 2009 |
Christopher Meldrum at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christopher Meldrum on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Dennis Langer | 1 | 9 |
| John Hamer | 1 | 7 |
| Keith Dionne | 1 | 3 |
| Pieter Burger | 1 | 1 |
| Thomas Kaiser | 1 | 1 |
| Ian J. Mehr | 1 | 1 |
| John B. Brennan | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.